Structure-activity profiles of eleutherobin analogs and their cross-resistance in Taxol-resistant cell lines Journal Article


Authors: McDaid, H. M.; Bhattacharya, S. K.; Chen, X. T.; He, L.; Shen, H. J.; Gutteridge, C. E.; Horwitz, S. B.; Danishefsky, S. J.
Article Title: Structure-activity profiles of eleutherobin analogs and their cross-resistance in Taxol-resistant cell lines
Abstract: Purpose: Eleutherobin, a natural product, is an antimitotic agent that promotes the polymerization of stable microtubules. Although its mechanism of action is similar to that of Taxol, its structure is distinct. A structure- activity profile of synthetic eleutherobin derivatives that have modifications at C3, C8 and C15 was undertaken to define the structural requirements for microtubule stabilization and cross-resistance in Taxol- resistant cell lines. Methods: The biological activity of five eleutherobin analogs was assessed using three techniques; (1) cytotoxicity and drug- resistance in three paired Taxol-sensitive and -resistant cell lines; (2) polymerization of microtubule protein in vitro in the absence of GTP and (3) induction of microtubule bundle formation in NIH3T3 cells. Results: Eleutherobin had an IC50 value comparable to that of Taxol, whereas neoeleutherobin, which has a carbohydrate domain that is enantiomeric with that of the parent compound, was less cytotoxic and had 69% of the maximum microtubule polymerization ability of eleutherobin. Both of these compounds exhibited cross-resistance in MDR1-expressing cell lines. Removal or replacement of the C15 sugar moiety resulted in reduced microtubule polymerization and cytotoxicity compared to eleutherobin and loss of cross- resistance in the cell lines SKVLB and J7-T3-1.6, both of which express high levels of P-glycoprotein. By contrast, removal of the urocanic acid group at C8 resulted in virtually complete abrogation of biological activity. The compound lost its ability to polymerize microtubules, and its cytotoxicity was reduced by a minimum of 2000-fold in lung carcinoma A549 cells. Conclusions: Removal or modification of the sugar moiety alters the cytotoxic potency of eleutherobin and its pattern of cross-resistance in Taxol- resistant cells, although such compounds retain a small percentage of the microtubule-stabilizing activity of eleutherobin. The N(1)-methylurocanic acid moiety of eleutherobin, or perhaps some other substituent at the C8 position, is essential for Taxol-like activity. These findings will be important for the future design and the synthesis of new and more potent eleutherobin derivatives.
Keywords: controlled study; unclassified drug; human cell; nonhuman; antineoplastic agents; paclitaxel; animal cell; mouse; lung non small cell cancer; cell line; calcium; cytotoxicity; drug resistance, neoplasm; tumor cells, cultured; structure activity relation; structure-activity relationship; tumor cell line; ovary carcinoma; microtubule assembly; macrophage; tubulin; guanosine triphosphate; alkaloids; microtubules; drug sensitivity; cell strain 3t3; p-glycoprotein; cross resistance; drug-resistance; taxol; diterpenes; glycoprotein p; structure-activity; eleutherobin; antimitotic agent; urocanic acid; microtubule protein; humans; human; priority journal; article; neoeleutherobin; skbii 13; skbii 294; skbii 296; skbii 298
Journal Title: Cancer Chemotherapy and Pharmacology
Volume: 44
Issue: 2
ISSN: 0344-5704
Publisher: Springer  
Date Published: 1999-06-01
Start Page: 131
End Page: 137
Language: English
DOI: 10.1007/s002800050957
PUBMED: 10412947
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 16 August 2016 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors